SINGLE-USE-SUPPORT-GMBH
17.10.2022 12:40:39 CEST | Business Wire | Press release
Austrian solution provider Single Use Support GmbH is expanding its product portfolio with new single-use bioprocess containers under the brand name IRIS. The pioneering company leverages its know-how to provide reliable process solutions in the field of biopharmaceutical fluid management, continuing to pursue its vendor-agnostic approach.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221017005451/en/
Robust storage and shipping of drug substance with IRIS single-use bag in RoSS® shell (Photo: Business Wire)
Single Use Support GmbH brings IRIS single-use bags to the biopharmaceutical market. The company’s extensive expertise in the behavior of different single-use containers and assemblies in critical process steps, such as protection, filling & draining, freezing & thawing, storage and shipping of drug substances, has now been translated into IRIS single-use bags. IRIS, the acronym for its key values: innovative, robust, individual and single-use, is the brand name for all Single Use Support sterile consumables.
Robust partner
Thomas Wurm, CEO and co-founder at Single Use Support, to the introduction of flexible single-use bag solutions: "Due to our supply chain resilience and our vendor-agnostic approach we are a robust partner when it comes to finding the optimal single-use system for any pharmaceutical manufacturer.” The launch of IRIS single-use systems does not affect the company’s dedication to providing vendor-agnostic process solutions. “The goal of Single Use Support is to simplify and optimize customer’s manufacturing processes, regardless of which bag is preferred” affirms Wurm.
Flexible single-use solutions
Depending on customers' needs IRIS single-use systems can be customized in terms of volume, number of ports and attached tubings and connectors. Thanks to lowest levels of extractables and leachables as well as highest integrity at temperatures as low as -150°C (-238°F), the bioprocess container is universally applicable for bioprocessing and cryopreservation of biologics, cell & gene therapies and more. Single Use Support will offer different types of biocontainers with multilayer films of polyethylene (PE) or ethylene vinyl acetate (EVA).
About Single Use Support GmbH
Single Use Support is the first provider to offer complete, flexible, and vendor-agnostic end-to-end solutions for cold chain logistics in pharmaceutical manufacturing based on single-use systems. Its innovative products, such as the RoSS® shell protection for all single-use bags, allow for high-value advanced therapies to be transported around the globe safely, in a sterile manner, and a permanently frozen state. Single Use Support GmbH has 140 employees, and had an annual revenue of over EUR 130 million in 2021.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221017005451/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom